Avaxia
Biologics, Inc., a clinical-stage biopharmaceutical company
developing gut-targeted therapeutics, announced today that Deborah S.
Hartman, Ph.D. has joined the company as ... read more
Avaxia
Biologics, Inc., a clinical-stage biopharmaceutical company
developing gut-targeted therapeutics, announced today that the first
patient has been dosed in a Phase ... read more
Avaxia
Biologics, Inc., a clinical-stage biopharmaceutical company
developing gut-targeted therapeutics, announced today that the company
raised $6.4 million in a Series B ... read more
LEXINGTON, Mass., Nov. 27, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the ... read more